Interactions : אינטראקציות

4.5 Interaction with other medicinal products and other forms of interaction

Myelotoxic interactions are to be expected in case of co-medication with other bone marrow toxic therapies (in particular other cytostatic agents, radiation).
Due to immunosuppressive action of cytarabine injection – viral, bacterial, fungal, parasitic, or saprophytic infections, in any location in the body may be associated with the use of cytarabine alone or in combination with other immunosuppressive agents following immunosuppressant doses that affect cellular or humoral immunity. These infections may be mild, but can be severe and at times fatal.


In patients receiving digoxin/β-acetyldigoxin concomitantly, digoxin levels must be monitored constantly during therapy with cytarabine. Even a single dose of cytarabine may lead to a reversible decrease in steady-state-digoxin plasma levels and to decreased renal elimination of glycosides. As this does apparently not occur with digitoxin, patients receiving a cytarabine therapy could be switched from digoxin to digitoxin.

Gentamicin-antagonism:
In vitro cytarabine seems to decrease the sensitivity of K. pneumoniae towards gentamicin. In case of unresponsiveness to gentamicin a replacement of the antibiotic agent might be indicated.

In isolated cases it was shown that the antimycotic activity of flucytosine can be inhibited by cytarabine.

Cytarabine may interfere with the determination of the protein content in the cerebrospinal fluid by means of turbidimetric measurement or a Folin-Ciocalteau assay.